Mallinckrodt

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.

Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.

InfaCare Pharmaceutical develops pharmaceuticals for the neonatal and pediatric patient population. They provide medicines to address unmet patient needs. Their areas of focus include autoimmune and rare diseases in specialty areas including neurology, rheumatology, nephrology, pulmonology, immunotherapy, neonatal respiratory critical care therapies, and gastrointestinal products.

Stratatech Corporation, a regenerative medicine company, engages in the development and commercialization of cell-based and tissue-engineered skin substitute products for therapeutic and research applications. The company specializes in human tissue substitutes generated with NIKS keratinocytes and cells derived from them for biological therapies. Its products include StrataGraft skin tissue, a temporary wound cover that promotes wound healing by the patient's own cells and improve the wound bed to receive autografts; and ExpressGraft skin tissue, a genetically enhanced tissue that produces various levels of natural wound healing and antimicrobial factors. The company was founded in 2000 and is based in Madison, Wisconsin.

Therakos provides extracorporeal photopheresis immune modulation therapy to enhance immunologic response. It offers Therakos Cellex Photopheresis System, which is used in conjunction with UVADEX (methoxsalen) Sterile Solution to treat the skin manifestations of CTCL that are unresponsive to other forms of treatment.

Ikaria develop and deliver innovative therapeutics and interventions to meet the significant needs of critically ill patients. It is our aim to be an indispensable partner to clinicians, providing help and critically caring just when patients need it the most.

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Our specific areas of focus are in the fields of neurology and nephrology and we are currently supporting research efforts in a variety of conditions having significant unmet medical need.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. On May 4, 2010 Cadence resubmitted a New Drug Application for its investigational product candidate, OFIRMEVTM (acetaminophen) injection for the treatment of pain and fever in adults and children. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date for OFIRMEV of November 4, 2010.

CNS Therapeutics is a private company based in St. Paul, Minn. CNS Therapeutics develops and markets safe, high-quality pharmaceuticals for site-specific delivery to the central nervous system to treat neurological disorders and chronic pain. In addition to its first FDA-approved product, Gablofen, CNS Therapeutics is currently collaborating with U.S. and international scientific experts to develop and test new treatments for pain and Parkinson's disease.

Nellcor Puritan Bennett manufactures patient monitoring instruments and disposable supplies for use in surgery.